Compounded Semaglutide: The Risks and Realities

When demand for semaglutide outran supply, a large market for compounded versions appeared: pharmacies and clinics mixing their own semaglutide products, often at a fraction of the branded price. For many people the appeal is simple: access and cost. But compounded GLP-1s occupy a genuinely different regulatory category from the branded drug, and understanding that difference is the whole point of this piece.

What does “compounded” semaglutide mean?

Branded semaglutide goes through the full approval process: defined manufacturing standards, batch testing, and an established safety and dosing record. Compounded products do not. Compounding is a legitimate pharmacy practice for tailoring medication to individual needs, but a compounded drug is not FDA-approved, and the agency does not verify its safety, effectiveness, or quality the way it does for the branded product.

That gap has practical consequences, and the FDA has flagged specific ones. The agency has identified compounded products using semaglutide salt forms (semaglutide sodium and semaglutide acetate) that differ from the active ingredient in approved drugs and have not been evaluated for safety or effectiveness. None of this means every compounded product is dangerous, but the quality floor is lower and far less verifiable.

The most concrete harm the FDA has documented is dosing error. In a July 26, 2024 alert, the agency reported that patients self-administering compounded injectable semaglutide had drawn up 5 to 20 times more than the intended dose. The causes were mundane and dangerous: instructions written in “units” rather than milligrams or milliliters, unfamiliarity with measuring from a vial with a syringe, and providers themselves miscalculating doses when converting mg to units. Reported adverse events included nausea, vomiting, abdominal pain, fainting, dehydration, gallstones, and acute pancreatitis, some serious enough to require hospitalization.

The core reality: with compounded semaglutide you are trading regulatory assurance for price and access. The drug may be the same molecule (or it may be a salt form the FDA hasn’t evaluated), and the guarantees around purity, dose accuracy, and consistency are not the same.

The main risk categories

• Ingredient identity: the FDA has found products using semaglutide sodium and acetate salt forms not equivalent to the approved active ingredient.
• Dosing errors: the FDA documented patients drawing 5–20x the intended dose from vials, in part because of unit-vs-milligram confusion. Overdose can mean severe nausea, vomiting, and dehydration.
• Sterility and quality: compounded drugs are not FDA-approved, and the agency does not verify their safety, effectiveness, or quality the way it does for branded products.
• Sourcing opacity: it can be hard to know where the active ingredient originated or how it was tested.
• Regulatory instability: availability of compounded versions can change quickly as supply shortages resolve and rules shift.

	FDA-approved (Ozempic / Wegovy)	Compounded
Manufacturer	Novo Nordisk	Compounding pharmacy
Identity and potency	Verified to approval standard	Not independently guaranteed
Sterility	Assured by the approval	Depends on the facility
Dosing format	Pre-filled pen, fixed increments	Often a vial and syringe — where the 5–20x errors arise
Trial evidence applies?	Yes — trials used this product	Not directly

Tirzepatide went through the same cycle on a different clock — its compounded window closed two months earlier at each stage, covered in compounded tirzepatide: what changed.

The administration risk is documented: a published case series of compounded semaglutide errors found two of three patients had given themselves tenfold doses, with vials and separate syringes named as the mechanism — GLP-1 overdose: what the reported cases actually show.

One part of the landscape has shifted since compounding peaked: two oral GLP-1s are now FDA approved, so a needle-free option no longer requires going outside the approved supply — see GLP-1 pills: oral semaglutide and orforglipron.

How should you think about the risk?

If you’re considering a compounded GLP-1, the most useful questions are about the pharmacy: Is it a licensed, reputable compounding pharmacy? What active ingredient form do they use, and from where? How is your dose prepared and measured? Generic “telehealth plus mystery vial” arrangements deserve far more skepticism than a transparent, licensed operation working with a prescribing clinician.

Frequently asked questions

What is compounded semaglutide?

Semaglutide prepared by a compounding pharmacy rather than manufactured by Novo Nordisk. It is not the FDA-approved product, and it does not carry the approved product’s guarantees of identity, potency, or sterility.

Is compounded semaglutide the same as Ozempic or Wegovy?

No. Same active molecule in principle, different manufacturing, different oversight. The trial evidence for semaglutide was generated on the approved product.

Is compounded semaglutide safe?

FDA has reported patients drawing 5–20x the intended dose, which is a dosing-error risk created by the format rather than by the molecule. Purity and sterility are separately unverified.

Why is compounded semaglutide available at all?

Compounding is permitted under specific conditions, and those conditions have shifted with drug shortages and FDA policy. The legal position is not static — see compounded peptides and the FDA’s shifting stance.

How do you avoid a dosing error?

The reported errors come from converting a prescribed dose into syringe units incorrectly. The arithmetic is covered in how to read an insulin syringe, and any dose question belongs with the prescriber.

The takeaway

Compounded semaglutide is cheaper and more accessible, and for some people that access is meaningful. But it is less regulated, the quality assurances are weaker, and the dosing-error risk is real and FDA-documented: patients have drawn 5 to 20 times the intended dose. Treat the price gap as information about what oversight you’re giving up, not as a free lunch, and make any decision with a clinician rather than a checkout page.

Sources

• FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products (FDA, July 2024)
• FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (U.S. Food and Drug Administration)